BBOT Stock Analysis: Buy, Sell, or Hold?
BBOT - BridgeBio Oncology Therapeutics, Inc. Common Stock
$8.09
-0.41 (-4.82%)
▼
5d:
-8.28%
30d:
+3.72%
90d:
-3.8%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
7d
Get Alerted When BBOT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BBOT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: BBOT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: BBOT is currently trading at $8.09, which is considered slightly low relative to its 30-day fair value range of $7.93 to $8.82.
Technical Outlook: Technically, BBOT is in a downtrend. The price is currently testing key support at $8.01. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $25.30 (+212.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BBOT is in a downtrend. The price is currently testing key support at $8.01. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $25.30 (+212.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.93 -
$8.82
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 212.7% below Wall St target ($25.30)
- CAUTION: Recommendation downgraded due to -8.3% 5-day decline
Trading Range Analysis
30-Day Trading Range
$7.93 -
$8.82
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$8.01
Resistance Level
$9.36
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.84
Wall Street Target
$25.30
(+212.7%)
Share & Embed Analysis
Last updated: August 03, 2026 3:36 AM ET
Data refreshes hourly during market hours. Next update: 4:36 AM
Data refreshes hourly during market hours. Next update: 4:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBOT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 59 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 56 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$33 | 58 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 HOLD |
